Influenza vaccines: Challenges and solutions

Cell Host and Microbe

Volumn 17, Issue 3, 2015, Pages 295-300

  Houser, Katherine ^a   Subbarao, Kanta ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; VIRUS ANTIGEN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY TITER; CROSS REACTION; HUMAN; IMMUNOGENICITY; INFLUENZA VACCINATION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA; VACCINE PRODUCTION; ZYGOTE; GENETIC REASSORTMENT; GENETICS; IMMUNOLOGY; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MUTATION; ORTHOMYXOVIRIDAE; PHARMACEUTICS; PHYSIOLOGY; PROCEDURES; TRENDS; UNITED STATES;

ANTIGENS, VIRAL; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MUTATION; ORTHOMYXOVIRIDAE; REASSORTANT VIRUSES; TECHNOLOGY, PHARMACEUTICAL; UNITED STATES;

EID: 84926160788     PISSN: 19313128     EISSN: 19346069     Source Type: Journal    
DOI: 10.1016/j.chom.2015.02.012     Document Type: Review

References (48)

1. R.D. Antrobus, P.J. Lillie, T.K. Berthoud, A.J. Spencer, J.E. McLaren, K. Ladell, T. Lambe, A. Milicic, D.A. Price, A.V. Hill, and S.C. Gilbert A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years PLoS ONE 7 2012 e48322
2. R.D. Antrobus, T.K. Berthoud, C.E. Mullarkey, K. Hoschler, L. Coughlan, M. Zambon, A.V. Hill, and S.C. Gilbert Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses Mol. Ther. 22 2014 233 238
3. T.M. Babu, M. Levine, T. Fitzgerald, C. Luke, and M.Y. Sangster Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine Vaccine 32 2014 6798 6804
4. M. Baz, C.J. Luke, X. Cheng, H. Jin, and K. Subbarao H5N1 vaccines in humans Virus Res. 178 2013 78 98
5. S. Black, U. Nicolay, T. Vesikari, M. Knuf, G. Del Giudice, G. Della Cioppa, T. Tsai, R. Clemens, and R. Rappuoli Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children Pediatr. Infect. Dis. J. 30 2011 1081 1085
6. K.L. Coelingh, C.J. Luke, H. Jin, and K.R. Talaat Development of live attenuated influenza vaccines against pandemic influenza strains Expert Rev. Vaccines 13 2014 855 871
7. D. Corti, and A. Lanzavecchia Broadly neutralizing antiviral antibodies Annu. Rev. Immunol. 31 2013 705 742
8. O. Even-Or, S. Samira, R. Ellis, E. Kedar, and Y. Barenholz Adjuvanted influenza vaccines Expert Rev. Vaccines 12 2013 1095 1108
9. B.M. Giles, and T.M. Ross A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets Vaccine 29 2011 3043 3054
10. B.M. Giles, S.J. Bissel, D.R. Dealmeida, C.A. Wiley, and T.M. Ross Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines Clin. Vaccine Immunol. 19 2012 128 139
11. B.M. Giles, C.J. Crevar, D.M. Carter, S.J. Bissel, S. Schultz-Cherry, C.A. Wiley, and T.M. Ross A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection J. Infect. Dis. 205 2012 1562 1570
12. L.A. Grohskopf, S.J. Olsen, L.Z. Sokolow, J.S. Bresee, N.J. Cox, K.R. Broder, R.A. Karron, E.B. Walter Centers for Disease Control and Prevention Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, 2014-15 influenza season MMWR Morb. Mortal. Wkly. Rep. 63 2014 691 697
13. M. Gurwith, M. Lock, E.M. Taylor, G. Ishioka, J. Alexander, T. Mayall, J.E. Ervin, R.N. Greenberg, C. Strout, and J.J. Treanor Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study Lancet Infect. Dis. 13 2013 238 250
14. C. Hannoun The evolving history of influenza viruses and influenza vaccines Expert Rev. Vaccines 12 2013 1085 1094
15. K. Haq, and J.E. McElhaney Immunosenescence: Influenza vaccination and the elderly Curr. Opin. Immunol. 29 2014 38 42
16. X.S. He, T.H. Holmes, C. Zhang, K. Mahmood, G.W. Kemble, D.B. Lewis, C.L. Dekker, H.B. Greenberg, and A.M. Arvin Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines J. Virol. 80 2006 11756 11766
17. H. Jin, and K. Subbarao Live attenuated influenza vaccine Curr. Top. Microbiol. Immunol. 386 2015 181 204
18. S. Khurana, W. Chearwae, F. Castellino, J. Manischewitz, L.R. King, A. Honorkiewicz, M.T. Rock, K.M. Edwards, G. Del Giudice, R. Rappuoli, and H. Golding Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus Sci. Transl. Med. 2 2010 ra5
19. S. Khurana, N. Verma, J.W. Yewdell, A.K. Hilbert, F. Castellino, M. Lattanzi, G. Del Giudice, R. Rappuoli, and H. Golding MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines Sci. Transl. Med. 3 2011 85ra48
20. F. Krammer, and P. Palese Influenza virus hemagglutinin stalk-based antibodies and vaccines Curr. Opin. Virol. 3 2013 521 530
21. J.H. Kreijtz, M. Goeijenbier, F.M. Moesker, L. van den Dries, S. Goeijenbier, H.L. De Gruyter, M.H. Lehmann, Gd. Mutsert, D.A. van de Vijver, and A. Volz Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial Lancet Infect. Dis. 14 2014 1196 1207
22. N.D. Lambert, I.G. Ovsyannikova, V.S. Pankratz, R.M. Jacobson, and G.A. Poland Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach Expert Rev. Vaccines 11 2012 985 994
23. J.E. Ledgerwood, C.J. Wei, Z. Hu, I.J. Gordon, M.E. Enama, C.S. Hendel, P.M. McTamney, M.B. Pearce, H.M. Yassine, J.C. Boyington VRC 306 Study Team DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials Lancet Infect. Dis. 11 2011 916 924
24. Y.T. Lee, K.H. Kim, E.J. Ko, Y.N. Lee, M.C. Kim, Y.M. Kwon, Y. Tang, M.K. Cho, Y.J. Lee, and S.M. Kang New vaccines against influenza virus Clin. Exp. Vaccine Res. 3 2014 12 28
25. G.M. Li, C. Chiu, J. Wrammert, M. McCausland, S.F. Andrews, N.Y. Zheng, J.H. Lee, M. Huang, X. Qu, and S. Edupuganti Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells Proc. Natl. Acad. Sci. USA 109 2012 9047 9052
26. C.K. Li, R. Rappuoli, and X.N. Xu Correlates of protection against influenza infection in humans - on the path to a universal vaccine? Curr. Opin. Immunol. 25 2013 470 476
27. H.I. Nakaya, J. Wrammert, E.K. Lee, L. Racioppi, S. Marie-Kunze, W.N. Haining, A.R. Means, S.P. Kasturi, N. Khan, and G.M. Li Systems biology of vaccination for seasonal influenza in humans Nat. Immunol. 12 2011 786 795
28. National Center for Immunization and Respiratory Diseases, CDC Centers for Disease Control and Prevention (CDC) Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009 MMWR Recomm. Rep. 58 RR-10 2009 1 8
29. K.G. Nicholson, A.E. Colegate, A. Podda, I. Stephenson, J. Wood, E. Ypma, and M.C. Zambon Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza Lancet 357 2001 1937 1943
30. S.E. Ohmit, J.G. Petrie, R.E. Malosh, B.J. Cowling, M.G. Thompson, D.K. Shay, and A.S. Monto Influenza vaccine effectiveness in the community and the household Clin. Infect. Dis. 56 2013 1363 1369
31. M.T. Osterholm, N.S. Kelley, A. Sommer, and E.A. Belongia Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis Lancet Infect. Dis. 12 2012 36 44
32. G.E. Price, M.R. Soboleski, C.Y. Lo, J.A. Misplon, C. Pappas, K.V. Houser, T.M. Tumpey, and S.L. Epstein Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses Vaccine 27 2009 6512 6521
33. G.E. Price, M.R. Soboleski, C.Y. Lo, J.A. Misplon, M.R. Quirion, K.V. Houser, M.B. Pearce, C. Pappas, T.M. Tumpey, and S.L. Epstein Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses PLoS ONE 5 2010 e13162
34. M.Y. Sangster, J. Baer, F.W. Santiago, T. Fitzgerald, N.A. Ilyushina, A. Sundararajan, A.D. Henn, F. Krammer, H. Yang, and C.J. Luke B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination Clin. Vaccine Immunol. 20 2013 867 876
35. D.J. Smith, A.S. Lapedes, J.C. de Jong, T.M. Bestebroer, G.F. Rimmelzwaan, A.D. Osterhaus, and R.A. Fouchier Mapping the antigenic and genetic evolution of influenza virus Science 305 2004 371 376
36. S. Sridhar, S. Begom, A. Bermingham, K. Hoschler, W. Adamson, W. Carman, T. Bean, W. Barclay, J.J. Deeks, and A. Lalvani Cellular immune correlates of protection against symptomatic pandemic influenza Nat. Med. 19 2013 1305 1312
37. K. Subbarao, and T. Joseph Scientific barriers to developing vaccines against avian influenza viruses Nat. Rev. Immunol. 7 2007 267 278
38. K. Subbarao, and Y. Matsuoka The prospects and challenges of universal vaccines for influenza Trends Microbiol. 21 2013 350 358
39. K.R. Talaat, M.E. Greenberg, M.H. Lai, G.F. Hartel, C.H. Wichems, S. Rockman, R.J. Jeanfreau, M.R. Ghosh, M.L. Kabongo, C. Gittleson, and R.A. Karron A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults J. Infect. Dis. 202 2010 1327 1337
40. K.R. Talaat, C.J. Luke, S. Khurana, J. Manischewitz, L.R. King, B.A. McMahon, R.A. Karron, K.D. Lewis, J. Qin, and D.A. Follmann A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response J. Infect. Dis. 209 2014 1860 1869
41. J.K. Taubenberger, and J.C. Kash Influenza virus evolution, host adaptation, and pandemic formation Cell Host Microbe 7 2010 440 451
42. S. Tong, Y. Li, P. Rivailler, C. Conrardy, D.A. Castillo, L.M. Chen, S. Recuenco, J.A. Ellison, C.T. Davis, and I.A. York A distinct lineage of influenza A virus from bats Proc. Natl. Acad. Sci. USA 109 2012 4269 4274
43. S. Tong, X. Zhu, Y. Li, M. Shi, J. Zhang, M. Bourgeois, H. Yang, X. Chen, S. Recuenco, and J. Gomez New world bats harbor diverse influenza A viruses PLoS Pathog. 9 2013 e1003657
44. J.J. Treanor, B.E. Wilkinson, F. Masseoud, J. Hu-Primmer, R. Battaglia, D. O'Brien, M. Wolff, G. Rabinovich, W. Blackwelder, and J.M. Katz Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans Vaccine 19 2001 1732 1737
45. R.A. Tripp, and S.M. Tompkins Virus-vectored influenza virus vaccines Viruses 6 2014 3055 3079
46. University of Cambridge (2014). W.C.C. "Mapping the Evolution of Pathogens." Retrieved Nov 1, 2014, from http://www.whocc.infectiousdisease.cam.ac.uk/antigenic-cartography.
47. WHO Influenza 2014 Seasonal
48. S.W. Yoon, R.J. Webby, and R.G. Webster Evolution and ecology of influenza A viruses Curr. Top. Microbiol. Immunol. 385 2014 359 375